Kim et al. observed that the MET inhibitor PHA-665752 shows a synergistic effect in combination with an EGFR inhibitor, erlotinib, in the triple negative breast cancer cell line, MDA-MB-468 [33], whereas the advantages of administrating anti-MET and anti-EGFR drugs simultaneously in non-small cell lung cancer was comprehensively reviewed by Padda et al. [34]. Here, EGFR is linked to triple-negative breast carcinoma.